Trial Profile

A Phase 1 Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lorlatinib (Primary)
Indications Brain metastases; Glioma; Lymphoma; Solid tumours
Focus Pharmacokinetics
Sponsors Pfizer

Most Recent Events

10 Jan 2022 Status changed from recruiting to discontinued due to lack of enrolment.
14 Jan 2020 Planned End Date changed from 25 Jan 2023 to 26 Apr 2023.
14 Jan 2020 Planned primary completion date changed from 16 Aug 2022 to 15 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com